Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762956 | 0.83 | KMT2A (0.44) | GAALMNAMCL1NPSR1HPGD | |
| SCHEMBL6503068 | 0.81 | MCL1 (0.42) | GAAMAPTLMNAMCL1NPSR1 | |
| SCHEMBL15413021 | 0.78 | LMNA (0.47) | MAPTLMNAATMHPGDL3MBTL1 | |
| SCHEMBL5763589 | 0.75 | ALDH1A1 (0.39) | GAAMCL1NPSR1HPGDL3MBTL1 | |
| SCHEMBL11326368 | 0.74 | KEAP1 (0.43) | GAALMNANPSR1KEAP1NFE2L2 | |
| SCHEMBL14356223 | 0.74 | PTGS2 (0.46) | GAALMNACYP2C19HPGDL3MBTL1 | |
| SCHEMBL9187527 | 0.71 | HMGB1 (0.40) | MCL1CYP1A2CYP3A4CYP2C19HPGD | |
| SCHEMBL2844789 | 0.71 | KEAP1 (0.43) | GAAMAPTLMNANPSR1KEAP1 | |
| SCHEMBL5367871 | 0.71 | MCL1 (0.55) | GAALMNAMCL1HPGDKDM4E | |
| SCHEMBL15412587 | 0.71 | OGG1 (0.43) | LMNAMCL1HPGDL3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | GAA 69/4885MAPT 4128/4885LMNA 4347/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | GAA 80/4885MAPT 4098/4885LMNA 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.